PROSTATE WARRIORS - The latest news about prostate cancer
  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact
  • Search
  • Menu Menu

Redefining Prostate Cancer Care: The LIBERTAS Trial

March 21, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 3/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-21 13:52:572025-03-21 13:52:57Redefining Prostate Cancer Care: The LIBERTAS Trial

Telomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity

March 19, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-19 17:34:402025-03-19 17:34:40Telomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity

Phase I Clinical Trial of AZD2284, AZD2287, and AZD2275

March 18, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-18 10:51:572025-03-18 10:51:57Phase I Clinical Trial of AZD2284, AZD2287, and AZD2275

Breaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer

March 18, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-18 07:42:352025-03-18 07:42:35Breaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer

Enzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial

March 17, 2025/0 Comments/in Post-hoc, Retrospective studies/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-17 11:53:082025-03-17 11:53:08Enzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial

Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision

March 14, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-14 08:30:572025-03-14 08:30:57Phase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision

AI-Designed ATR Inhibitors Advance to Preclinical Testing

March 13, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-13 09:01:222025-03-13 09:01:22AI-Designed ATR Inhibitors Advance to Preclinical Testing

FutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705

March 11, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 3/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-03-11 07:35:582025-03-11 07:35:58FutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
Page 12 of 35«‹1011121314›»

Menu

  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact

Categories

Archives

  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • September 2023

Project Navigator


Let's try to finance it!

A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.

Tags

abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR HRRm immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics

Latest Posts

  • Newsletter 24/2025 June 15, 2025
  • Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells June 13, 2025
  • ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations) June 13, 2025
  • UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025
© Copyright 2024 - PROSTATE WARRIORS - The latest news about prostate cancer
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only